Allergan Aesthetics to Present New Weight Loss Research at ASDS 2026

Allergan Aesthetics, an AbbVie company, will present new research on aesthetic treatments for people experiencing medical weight loss at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego, California.

Announced on November 3, 2026, the company plans to present nine scientific abstracts during the meeting, which will take place from November 5 to 8. The research will cover aesthetic care following medical weight loss, facial treatments, skin quality, body contouring and new developments in cosmetic treatments.

A major focus will be on patients taking glucagon-like peptide-1 (GLP-1) medicines for weight management. As the use of these medicines continues to grow, more patients are seeking aesthetic treatments to address changes in their facial appearance and skin quality following weight loss.

Allergan Aesthetics will present findings from two Phase 4 studies examining the effects of aesthetic treatments in patients undergoing medical weight loss.

One study, titled HARMONY IN DIVERSITY: Improved Satisfaction With Aesthetic Appearance and Psychosocial Function Following Multimodal Aesthetic Treatment in a Medical Weight Loss Cohort, will examine whether combining different aesthetic treatments can improve patient satisfaction and psychological well-being.

The second study will evaluate facial appearance and psychological outcomes following treatment with hyaluronic acid-based injectable products in patients who have experienced medical weight loss.

The research aims to provide a better understanding of how weight loss can affect facial appearance and how aesthetic treatments may help address these changes. It will also examine patient satisfaction and psychosocial outcomes, rather than focusing only on physical improvements.

Another key presentation will focus on trenibotulinumtoxinE (trenibotE), an investigational neurotoxin being developed for cosmetic use. Researchers will present a digital image analysis comparing changes in glabellar lines, commonly known as frown lines between the eyebrows, and brow position following treatment with trenibotE and BOTOX Cosmetic (onabotulinumtoxinA).

The analysis will use digital imaging to provide objective measurements that complement traditional clinical assessments. The findings will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session on November 8.

Beyond these studies, Allergan Aesthetics will share additional research on multimodal treatments for the face and neck, including patient satisfaction and improvements in psychosocial well-being.

The company will also present research on topical exosome-based skincare products. These studies will examine the potential of cosmetic human fibroblast-derived exosome serums to support skin quality, improve skincare outcomes and assist recovery following aesthetic procedures such as radiofrequency microneedling and non-ablative laser treatments.

Another area of research will focus on body contouring. The presentation will examine different treatment sequences combining cryolipolysis, a technique that uses controlled cooling to target fat cells, with electromagnetic muscle stimulation for abdominal body contouring.

In addition to the scientific presentations, Allergan Aesthetics will host an expert panel titled The Aesthetics Evolution: Inside the Changing Consumer Landscape on November 5. The discussion will explore changing consumer expectations, common misconceptions about aesthetic procedures and the growing impact of medical weight loss on the aesthetics industry.

The panel will draw on findings from the company’s What Consumers Really Want report and feature experts including Tiffany Libby, Anthony Rossi, Joely Kaufman-Janette and Vince Bertucci.

Darin Messina, Senior Vice President and Head of Aesthetics Research and Development at AbbVie, said the company remains focused on understanding changing patient needs and generating scientific evidence to support informed treatment decisions.

The presentations reflect the growing connection between medical weight management and aesthetic medicine. As more people use GLP-1 medicines to lose weight, demand is increasing for treatments that address changes in facial volume, skin quality and overall appearance.

Through its research programme, Allergan Aesthetics aims to provide healthcare professionals with more information to guide treatment decisions and support patients throughout their aesthetic care journeys.

Comments (0)
Add Comment